INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) saw unusually large options trading on Friday. Investors bought 3,375 put options on the company. This is an increase of approximately 101% compared to the average daily volume of 1,681 put options.
INmune Bio Stock Down 3.5%
Shares of INMB stock traded down $0.26 during trading hours on Friday, hitting $6.99. 199,882 shares of the company's stock traded hands, compared to its average volume of 298,603. The stock's fifty day simple moving average is $7.54 and its two-hundred day simple moving average is $7.27. INmune Bio has a 12-month low of $4.32 and a 12-month high of $10.50. The stock has a market cap of $160.52 million, a price-to-earnings ratio of -3.62 and a beta of 1.55.
INmune Bio (NASDAQ:INMB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43). The firm had revenue of $0.05 million during the quarter. On average, equities analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.
Institutional Investors Weigh In On INmune Bio
A number of large investors have recently made changes to their positions in INMB. Wells Fargo & Company MN increased its holdings in INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after acquiring an additional 2,155 shares in the last quarter. Beacon Pointe Advisors LLC bought a new position in shares of INmune Bio in the fourth quarter worth approximately $48,000. Quarry LP purchased a new stake in INmune Bio in the 1st quarter worth $48,000. JPMorgan Chase & Co. boosted its stake in shares of INmune Bio by 93.0% in the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock worth $53,000 after acquiring an additional 5,461 shares during the period. Finally, Two Sigma Advisers LP bought a new position in shares of INmune Bio in the fourth quarter worth about $59,000. 12.72% of the stock is currently owned by institutional investors.
About INmune Bio
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
